Jim Simons’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Jim Simons’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-41,100	Closed	-$5.01M	–	3745
2025 Q4	$5.01M	Buy	+41,100	New	+$4.71M	0.01%	1303
2025 Q3	–	Sell	-48,800	Closed	-$4.05M	–	3995
2025 Q2	$4.05M	Buy	+48,800	New	+$3.89M	0.01%	1653
2025 Q1	–	Sell	-5,500	Closed	-$495K	–	3890
2024 Q4	$495K	Buy	+5,500	New	+$533K	﹤0.01%	2848
2023 Q2	–	Sell	-18,200	Closed	-$1.39M	–	4316
2023 Q1	$1.39M	Buy	+18,200	New	+$1.51M	﹤0.01%	2249
2022 Q4	–	Sell	-4,100	Closed	-$325K	–	4460
2022 Q3	$325K	Sell	4,100 -7,100	-63%	-$599K	﹤0.01%	3178
2022 Q2	$832K	Sell	11,200 -41,100	-79%	-$3.09M	﹤0.01%	2831
2022 Q1	$4.7M	Buy	+52,300	New	+$4.83M	0.01%	1636
2020 Q3	–	Sell	-26,900	Closed	-$3.01M	–	3746
2020 Q2	$3.01M	Buy	+26,900	New	+$2.65M	﹤0.01%	1932

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jim Simons's XBI Position: Q1 2026 in Review

Jim Simons sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 41,100 shares — an estimated $5.01M sold.

Jim Simons first reported a position in XBI in Q2 2020 and held it in 8 quarters. The position peaked at $5.01M in Q4 2025. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Jim Simons reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Jim Simons sold 41,100 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $5.01M.
Jim Simons first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 8 quarters.
Jim Simons's State Street SPDR S&P Biotech ETF position peaked at $5.01M in Q4 2025.
815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.